Inverse agonists are ligands that preferentially stabilize inactive conformations of G protein-coupled receptors. In a range of systems, sustained treatment with inverse agonists can produce substantially greater upregulation of receptor levels than antagonists. The use of constitutively active mutant receptors can exaggerate this effect but may also allow agonists and antagonists to mimic the effect by preventing denaturation of the mutant receptor polypeptide. In this review Graeme Milligan and Richard Bond consider the basis for these effects and their therapeutic implications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0165-6147(97)01139-5 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!